Clinical Study of Apatinib Combined with Concurrent Chemoradiotherapy in the Treatment of Medium-Term Advanced Cervical Cancer
Objective To explore the clinical effect of apatinib combined with concurrent chemoradiotherapy in the treatment of medium-term advanced cervical cancer.Methods 82 patients with medium-term advanced cervical cancer admitted to our hospital from January 2020 to December 2022 were selected and randomly divided into control group(41 cases)and study group(41 cases).The control group was treated with chemoradiotherapy,and the study group was treated with apatinib combined with concurrent chemoradiotherapy.The short-term efficacy and adverse reactions of the two groups were compared.Results The objective response rate(ORR)of the study group was 73.17％,higher than 41.46％of the control group(P＜0.05);No statistical difference was found in the disease control rate(DCR)between the two groups(P＞0.05).No statistical difference was found in the incidence of thrombocytopenia,leukopenia,gastrointestinal injury,anemia,and alopecia between the two groups during treatment(P＞0.05);The incidences of hypertension,hand foot syndrome,and proteinuria in the study group were higher than those in the control group(P＜0.05).Conclusions Apatinib combined with concurrent chemoradiotherapy has significant short-term effect in the treatment of medium-term advanced cervical cancer,but has an increase of adverse reactions among patients.It is necessary to strengthen monitoring during treatment,take timely measures to alleviate the discomfort of patients,and ensure the safety of medication while ensuring treatment effect.
国家科技期刊平台
NSTL
万方数据
